When Stéphane Bancel left his job at a French medical diagnostics firm to join Moderna in 2011, he told his wife he thought the new job had only a “5% chance” of working out, says The Sunday Times. Moderna then was a heavily loss-making fledgling start-up, majoring on an experimental and unproven technology – messenger RNA. Yet a decade and a deadly virus on, it’s clear his career gamble has paid off. As one associate observes, “the pandemic came almost as a blessing to prove the technology”.
Big, hairy, audacious goals
The Boston-based company was the first in America to begin trials of a vaccine based on mRNA (the same gene-based approach used by Germany’s BioNTech) and has since become “one of the leaders in the fight against Covid-19”. Unlike AstraZeneca – an early investor which has rolled out its own vaccine at cost – Moderna is making “serious money from its contribution”, charging between $33 and $37 per dose as it distributes hundreds of millions of jabs worldwide. Since mid-March 2020, its shares have risen by more than 500%, taking its stockmarket value to $57bn. Its French boss, who has an 8% stake, is now worth an estimated $4.6bn.
The challenge of producing a vaccine from scratch in double-quick time was meat and drink to Bancel, 48, who thrives on setting himself ambitious challenges, says the Financial Times. Long before the virus even had a name, Bancel spent his Christmas break tracking its movements in China. According to Moderna’s second-in-command, Stephen Hoge, who has worked with him almost since Moderna’s inception, quite often Bancel would outline some “big, hairy, audacious goal… and I’m like, ‘I don’t know what planet you’re on’. He’s... expansive in his thinking”. Unusually for a biotech chief, he’s an engineer, not a biologist. The point, says a former colleague, is that “he has this capacity to work like a dog... to learn about science”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Born in 1972, Bancel grew up in Marseilles and might be described as the perfect professional amalgam of his parents – his father was an engineer and his mother a doctor. Bancel had a “precocious interest in maths and science” and “tinkered with computers” as a child, notes a 2016 Harvard Innovation Labs profile. He “imagined he would one day work in technology”. After studying chemical and biomolecular engineering at École Centrale Paris, Bancel moved to the US to do a masters in biological engineering at Minnesota University. His first job was at diagnostics firm BioMérieux, which sponsored an MBA at Harvard Business School. At 29, he joined the US pharmaceuticals firm Eli Lilly, before returning to lead BioMérieux when he was just 34. A few years later, he took his gamble with Moderna.
The Amazon of mRNA
“Bancel attributes a great deal of his success as an executive to the breadth of the liberal arts education he received in France.” Others think it owes more to Silicon Valley. A “master fundraiser” in the days before Moderna’s blockbusting 2018 float, he used to talk about admiring Uber’s “platform” strategy, says the FT. Some of Uber boss Travis Kalanick’s controversial modus operandi may have rubbed off too. Moderna’s “hard-charging culture shook some former employees used to working at biotechs that operate more like academia”. His ambition hasn’t changed: he still wants to make Moderna, which has 23 products in development, “the Amazon of mRNA”.
-
Barclays warns of significant rise in social media investment scamsInvestment scam victims are losing an average £14k, with 61% of those falling for one over social media. Here's how to spot one and keep your money safe
-
Over a thousand savings accounts now offer inflation-busting rates – how long will they stick around?The rate of UK inflation slowed again in March, boosting the opportunity for savers to earn real returns on cash in the bank. But you will need to act fast to secure the best deals.
-
Should your business invest in a VoIP phone service?Here's what you need to know about VOIP (voice over IP) services before landlines go digital in 2025.
-
The end of China’s boomLike the US, China too got fat on fake money. Now, China's doom is not far away.
-
The many frauds of Dozy Mmobuosi, failed Sheffield United ownerProfile Dozy Mmobuosi was a big-hitter with a fintech empire when he stepped in to rescue a failing Yorkshire football club. But he was not quite the saviour he seemed.
-
What is the future of Royal Mail in the UK?With fewer of us sending letters and parcels, the Royal Mail is finding dealing with the nation’s post is an increasingly unprofitable and costly business.
-
What's the secret of Manolo Blahnik's success?Fashion maestro Manolo Blahnik shows little sign of slowing down at 81, and his company notched up a record financial year in 2022. What is the secret of his success?
-
Michelle Mone's "tough year of pain"Michelle Mone liked to portray herself as a working-class heroine who worked her way to the top through grit and determination. But her pedestal is built on sand.
-
Trevor Milton, the Elon Musk wannabe, is jailed for fraudThe former CEO of Nikola, Trevor Milton, has been found guilty of lying about the development of the company's electric trucks.
-
Directors should think twice before waiving limited liabilityShould small-business directors ever provide a personal guarantee in return for bank finance?
